公开(公告)号：US12066429B2

公开(公告)日：2024-08-20

申请号：US16913376

申请日：2020-06-26

Applicant: National University Corporation Tokyo Medical and Dental University ,  Nippon Zoki Pharmaceutical Co., Ltd.

Inventor： Hiroshi Asahara ,  Tomoki Chiba ,  Kentaro Abe

IPC: C12N15/11 ,  C12N15/10 ,  C12N15/113 ,  C12N15/63 ,  G01N33/50

CPC classification number: G01N33/5023 ,  C12N15/1086 ,  C12N15/113 ,  C12N15/63 ,  C12N2310/14 ,  C12N2310/18 ,  C12N2320/10 ,  C12N2320/50 ,  G01N2500/02 ,  G01N2500/10

Abstract: Provided are an expression inhibitor of an inflammation promoting factor based on the discovery of a new factor influencing the expression amount/level of an inflammation promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for immune diseases, inflammatory diseases, painful conditions and similar. More specifically provided are: an expression inhibitor of an inflammation promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS2 expression inhibitor and RBMS2 function inhibitor; a screening method using as an indicator the expression or the function of RBMS2; an expression cassette useful for the method; as well as a diagnostic agent containing a product detection agent for RBMS2 gene expression and disease detection method using as an indicator RBMS2 gene expression amount/level.

公开(公告)号：US20240270851A1

公开(公告)日：2024-08-15

申请号：US18567990

申请日：2022-06-06

Applicant: THE U.S.A., as represented by the Secretary, Department of Health and Human Services

Inventor： Mitchell Ho ,  Glenn Merlino ,  Dan Li ,  Hejiao English ,  Chi-Ping Day

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2827 ,  A61K39/4631 ,  A61K39/464402 ,  A61P35/00 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/569

Abstract: Single-domain shark variable new antigen receptor (VNAR) monoclonal antibodies that specifically bind programmed death-ligand 1 (PD-L1) are described. The PD-L1-specific VNAR antibodies are capable of binding PD-L1-expressing tumor cells from human, mouse and canine origin. Immune cells expressing chimeric antigen receptors (CARs) developed using the VNAR antibodies can be used to kill PD-L1-positive tumor cells, for example in animal models of liver cancer and breast cancer.

公开(公告)号：US20240270835A1

公开(公告)日：2024-08-15

申请号：US18442575

申请日：2024-02-15

Applicant: AMGEN INC.

Inventor： Christopher J. Paszty

IPC: C07K16/22 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/60 ,  C07K14/51 ,  C07K14/76 ,  C07K14/79 ,  C07K16/18 ,  C12N15/63

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  C07K14/51 ,  C07K14/76 ,  C07K14/79 ,  C07K16/18 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.

公开(公告)号：US20240270813A1

公开(公告)日：2024-08-15

申请号：US18557647

申请日：2022-05-02

Applicant: University Of Pittsburgh - Of The Commonwealth System Of Higher Education ,  BlueSphere Bio, Inc.

Inventor： Sawa Ito ,  Warren David Shlomchik ,  Mark Jay Shlomchik ,  Constantinos George Panousis ,  Josh Kim ,  Erik Martin ,  Daniel Wikenheiser

IPC: C07K14/725 ,  A61P35/00 ,  C12N5/0783 ,  C12N15/63

CPC classification number: C07K14/7051 ,  A61P35/00 ,  C12N5/0636 ,  C12N15/63 ,  C07K2317/565 ,  C12N2510/00

Abstract: Provided herein are T cell receptors (TCRs) or antigen-binding fragments thereof, such as those that recognize or bind a hematopoictically-restricted minor histocompatibility antigen, e.g., HA-1. In particular, the present disclosure relates to TCRs that bind or recognize particular HA-1 peptides in the context of a major histocompatibility complex (MHC) molecule. The present disclosure further relates to nucleic acids encoding such TCRs, engineered cells comprising such TCRs, methods of isolating such TCRs, and uses thereof, for example, in cell therapy.

公开(公告)号：US20240263183A1

公开(公告)日：2024-08-08

申请号：US18426680

申请日：2024-01-30

Applicant: PRECIGEN, INC.

Inventor： Rutul R. SHAH ,  Thomas D. REED ,  Cheryl G. BOLINGER

IPC: C12N15/63 ,  C07K14/54 ,  C07K14/725 ,  C12N15/10 ,  C12N15/85 ,  G01N33/68

CPC classification number: C12N15/635 ,  C07K14/5443 ,  C07K14/7051 ,  C12N15/1055 ,  C12N15/63 ,  C12N15/85 ,  G01N33/6845 ,  C07K2319/80 ,  C12N2800/90

Abstract: Disclosed herein are polynucleotides encoding ligand-inducible gene switch polypeptides, and systems comprising gene switch polypeptides for modulating the expression of a heterologous gene and an interleukin in a host cell. The compositions, methods and systems described herein facilitate ligand dependent expression of polypeptides including but not limited to cytokines and antigen binding polypeptides.

公开(公告)号：US12054702B2

公开(公告)日：2024-08-06

申请号：US17150878

申请日：2021-01-15

Applicant: DNA TWOPOINTO INC.

Inventor： Jeremy Minshull ,  Mark Welch ,  Sridhar Govindrajan ,  Maggie Lee ,  Kate Caves ,  Jon Ness

IPC: C12N9/00 ,  A61K8/66 ,  A61K47/42 ,  C07K14/435 ,  C12N1/16 ,  C12N1/18 ,  C12N9/12 ,  C12N15/10 ,  C12N15/52 ,  C12N15/62 ,  C12N15/63 ,  C12N15/81 ,  C12N15/85 ,  C12N15/90 ,  C12N15/67 ,  C12R1/84 ,  C12R1/865

CPC classification number: C12N1/165 ,  C12N1/185 ,  C12N9/12 ,  C12N9/1241 ,  C12N15/1082 ,  C12N15/52 ,  C12N15/625 ,  C12N15/63 ,  C12N15/81 ,  C12N15/815 ,  C12N15/85 ,  C12N15/8509 ,  C12N15/90 ,  C12Y207/00 ,  C12Y207/07 ,  C07K2319/09 ,  C12N15/67 ,  C12N2800/90 ,  C12N2830/007 ,  C12N2830/40 ,  C12N2830/42 ,  C12N2840/203 ,  C12R2001/84 ,  C12R2001/865

Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.

公开(公告)号：US12054517B2

公开(公告)日：2024-08-06

申请号：US17734432

申请日：2022-05-02

Applicant: The Regents of the University of California

Inventor： Yoshikazu Takada ,  Yoko Takada

IPC: C07K14/00 ,  A61P29/00 ,  C12N15/63

CPC classification number: C07K14/001 ,  A61P29/00 ,  C12N15/63 ,  C07K2319/034

Abstract: The present invention resides in the discovery that the specific interaction between Myeloid Differentiation factor 2 (MD2) and integrin, especially integrin αvβ3, is involved in cellular signaling mediated by MD2-integrin, such as inflammatory response including sepsis. Thus, this invention provides for a novel method for inhibiting integrin signaling by using an inhibitor of MD2-integrin binding, such as a dominant negative mutant of MD2 without integrin-binding capability. A method for identifying inhibitors of MD2-integrin binding is also described. Further disclosed are polypeptides, nucleic acids, host cells, and corresponding compositions for inhibiting MD2-integrin signaling.

公开(公告)号：US20240252622A1

公开(公告)日：2024-08-01

申请号：US18615472

申请日：2024-03-25

Applicant: INSTITUT PASTEUR

Inventor： Etienne SIMON-LORIERE ,  Matthieu PROT ,  Xavier MONTAGUTELLI

IPC: A61K39/215 ,  A61K39/00 ,  C12N15/63 ,  C12P19/34

CPC classification number: A61K39/215 ,  C12N15/63 ,  C12P19/34 ,  A61K2039/51

Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

公开(公告)号：US12049509B2

公开(公告)日：2024-07-30

申请号：US17196135

申请日：2021-03-09

Applicant: Zoetis Services LLC

Inventor： Sebastian C. J. Steiniger ,  William Dunkle ,  Catherine Rugg ,  Steven A. Dunham

IPC: C12N15/13 ,  A61K31/713 ,  A61K39/395 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P29/02 ,  C07K16/22 ,  C07K16/28 ,  C12N15/11 ,  C12N15/63 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K31/713 ,  A61K39/39533 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P29/02 ,  C07K16/22 ,  C12N15/11 ,  C12N15/63 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment of NGF related disorders, particularly in for the management of pain.

公开(公告)号：US12049507B2

公开(公告)日：2024-07-30

申请号：US17192368

申请日：2021-03-04

Applicant: Zoetis Services LLC

Inventor： Sebastian C. J. Steiniger ,  William Dunkle ,  Catherine Rugg ,  Steven A. Dunham

IPC: A61K39/395 ,  A61K31/713 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P29/02 ,  C07K16/22 ,  C07K16/28 ,  C12N15/11 ,  C12N15/63 ,  A61K38/00 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K31/713 ,  A61K39/39533 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P29/02 ,  C07K16/22 ,  C12N15/11 ,  C12N15/63 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment of NGF related disorders, particularly in for the management of pain.